Trump Administration Medicaid Obesity Drug Coverage Pledge Faces Implementation Hurdles
President Trump's commitment to expand Medicaid coverage for weight loss medications has not materialized in practice. The pledge aimed to make expensive obesity drugs accessible to low-income beneficiaries, but implementation has stalled. The development affects Medicaid agencies planning pharmacy benefits and managed care organizations managing pharmacy carve-ins. The gap between the announced policy intent and actual coverage expansion leaves states without federal guidance on obesity medication coverage requirements or financing mechanisms.
State Medicaid agencies and MCOs managing pharmacy benefits face continued uncertainty on obesity drug coverage mandates, formulary design, and federal financial participation for a high-cost therapeutic class affecting millions of beneficiaries.
Pharmacy · Managed Care
You might also like